A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council
The decision to initiate JAKi treatment should be shared between the patient and provider, accounting for AD severity and personal risk-benefit assessment, including consideration of baseline health risk factors, monitoring requirements and treatment costs.
Authors
- Dedee Frances Murrell (ORCID: https://orcid.org/0000-0003-2971-0199)
- Melinda Gooderham (ORCID: https://orcid.org/0000-0001-8926-0113)
- David Rosmarin (ORCID: https://orcid.org/0000-0003-2786-0708)
- Jonathan I. Silverberg (ORCID: https://orcid.org/0000-0003-3686-7805)
- Jacob Pontoppidan Thyssen (ORCID: https://orcid.org/0000-0003-3770-1743)
- Eric L. Simpson (ORCID: https://orcid.org/0000-0003-0853-0252)
- Yael Renert‐Yuval (ORCID: https://orcid.org/0000-0002-2876-3048)
- Valéria Aoki (ORCID: https://orcid.org/0000-0003-4256-4413)
- Amy S. Paller (ORCID: https://orcid.org/0000-0001-6187-6549)
- Emma Guttman‐Yassky (ORCID: https://orcid.org/0000-0002-9363-324X)
- Raj Chovatiya (ORCID: https://orcid.org/0000-0001-6510-399X)
- Michael J. Cork (ORCID: https://orcid.org/0000-0003-4428-2428)
- Robert Bissonnette (ORCID: https://orcid.org/0000-0001-5927-6587)
- Adriane A. Levin
- Sonja Ständer (ORCID: https://orcid.org/0000-0003-3612-7786)
- Jill I. Olydam (ORCID: https://orcid.org/0000-0002-7391-5266)
- Simon G. Danby (ORCID: https://orcid.org/0000-0001-7363-140X)
- Andrew F Alexis (ORCID: https://orcid.org/0000-0002-1351-9165)
- Carter Haag (ORCID: https://orcid.org/0000-0003-4250-0591)
- Ida Vittrup (ORCID: https://orcid.org/0000-0002-3192-6135)
- Yael A. Leshem
- Lawrence F. Eichenfield (ORCID: https://orcid.org/0000-0002-2760-0474)
- Alan D. Irvine (ORCID: https://orcid.org/0000-0002-9048-2044)
- Raquel Leão Orfali (ORCID: https://orcid.org/0000-0002-2807-1404)
- Andrew Blauvelt (ORCID: https://orcid.org/0000-0002-2633-985X)
- Kilian Eyerich (ORCID: https://orcid.org/0000-0003-0094-2674)
- DirkJan Hijnen (ORCID: https://orcid.org/0000-0003-3379-3425)
- Nick Stefanovic
- Norito Katoh
- JiaDe Yu
- Gail Todd
Institutions
- Northwestern University (US)
- Harvard University (US)
- University of Cape Town (ZA)
- University of Freiburg (DE)
- Tel Aviv University (IL)
- Oregon Health & Science University (US)
- Universidade de São Paulo (BR)
- George Washington University (US)
- Queen's University (CA)
- Trinity College Dublin (IE)
- Cornell University (US)
- University of Münster (DE)
- Rabin Medical Center (IL)
- Frederiksberg Hospital (DK)
- Copenhagen University Hospital (DK)
- University of California San Diego (US)
- Massachusetts General Hospital (US)
- Schneider Children's Medical Center (IL)
- St George Hospital (AU)
- Oregon Medical Research Center (US)
- Innovaderm (Canada) (CA)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- University of Sheffield (GB)
- Erasmus University Rotterdam (NL)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1093/bjd/ljae342
- Citations
- 33
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 17.64
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Celgene
- CSL Behring
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Valeant Pharmaceuticals International
- National Jewish Health
- Dermira
- BioCryst
- Kyowa Kirin Pharmaceutical Development
- Kiniksa Pharmaceuticals
- Torii Pharmaceutical
- Incyte
- Castle Biosciences
- Otsuka Pharmaceutical
- Galderma
- Sun Pharma
- LEO Pharma
- Genentech
- Sanofi Genzyme
- Eli Lilly Japan